Need Help?

PPGL RNA-Seq dataset

Dataset includes fastq files for RNA-Seq experiments for tumor samples of PPGL patients. Single end reads fastq files are available for 102 different samples

Request Access

Policy for access to WES and RNA-Seq data of pheochromocytomas and paragangliomas

DATA ACCESS AGREEMENT These terms and conditions govern access to the managed access datasets (details of which are set out in Appendix I) to which the User Institution has requested access. The User Institution agrees to be bound by these terms and conditions. Definitions Authorised Personnel: The individuals at the User Institution to whom HECG-BU grants access to the Data. This includes the User, the individuals listed in Appendix II and any other individuals for whom the User Institution subsequently requests access to the Data. Details of the initial Authorised Personnel are set out in Appendix II. Data: The managed access datasets to which the User Institution has requested access. Data Producers: HECG-BU and the collaborators listed in Appendix I responsible for the development, organisation, and oversight of these Data. External Collaborator: A collaborator of the User, working for an institution other than the User Institution. Project: The project for which the User Institution has requested access to these Data. A description of the Project is set out in Appendix II. Publications: Includes, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Research Participant: An individual whose data form part of these Data. Research Purposes: Shall mean research that is seeking to advance the understanding of genetics and genomics, including the treatment of disorders, and work on statistical methods that may be applied to such research. User: The principal investigator for the Project. User Institution(s): The Institution that has requested access to the Data. HECG-BU: Hereditary Endocrine Cancer Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain and Bioinformatics Unit, Structural Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain 1. The User Institution agrees to only use these Data for the purpose of the Project (described in Appendix II) and only for Research Purposes. The User Institution further agrees that it will only use these Data for Research Purposes which are within the limitations (if any) set out in Appendix I. 2. The User Institution agrees to preserve, at all times, the confidentiality of these Data. In particular, it undertakes not to use, or attempt to use these Data to compromise or otherwise infringe the confidentiality of information on Research Participants. Without prejudice to the generality of the foregoing, the User Institution agrees to use at least the measures set out in Appendix I to protect these Data. 3. The User Institution agrees to protect the confidentiality of Research Participants in any research papers or publications that they prepare by taking all reasonable care to limit the possibility of identification. 4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction. 5. The User Institution agrees only to transfer or disclose these Data, in whole or part, or any material derived from these Data, to the Authorised Personnel. Should the User Institution wish to share these Data with an External Collaborator, the External Collaborator must complete a separate application for access to these Data. 6. The User Institution agrees that the Data Producers, and all other parties involved in the creation, funding or protection of these Data: a) make no warranty or representation, express or implied as to the accuracy, quality or comprehensiveness of these Data; b) exclude to the fullest extent permitted by law all liability for actions, claims, proceedings, demands, losses (including but not limited to loss of profit), costs, awards damages and payments made by the Recipient that may arise (whether directly or indirectly) in any way whatsoever from the Recipient’s use of these Data or from the unavailability of, or break in access to, these Data for whatever reason and; c) bear no responsibility for the further analysis or interpretation of these Data. 7. The User Institution agrees to follow the Fort Lauderdale Guidelines (http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_communications/documents/web_document/wtd003207.pdf ) and the Toronto Statement (http://www.nature.com/nature/journal/v461/n7261/full/461168a.html). This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data. 8. The User Institution agrees to follow the Publication Policy in Appendix III. This includes respecting the moratorium period for the Data Producers to publish the first peer-reviewed report describing and analysing these Data. 9. The User Institution agrees not to make intellectual property claims on these Data and not to use intellectual property protection in ways that would prevent or block access to, or use of, any element of these Data, or conclusion drawn directly from these Data. 10. The User Institution can elect to perform further research that would add intellectual and resource capital to these data and decide to obtain intellectual property rights on these downstream discoveries. In this case, the User Institution agrees to implement licensing policies that will not obstruct further research and to follow the U.S. National Institutes of Health Best Practices for the Licensing of Genomic Inventions (2005) (https://www.icgc.org/files/daco/NIH_BestPracticesLicensingGenomicInventions_2005_en.pdf ) in conformity with the Organisation for Economic Co-operation and Development Guidelines for the Licensing of the Genetic Inventions (2006) (http://www.oecd.org/science/biotech/36198812.pdf ). 11. The User Institution agrees to destroy/discard the Data held, once it is no longer used for the Project, unless obliged to retain the data for archival purposes in conformity with audit or legal requirements. 12. The User Institution will notify HECG-BU within 30 days of any changes or departures of Authorised Personnel. 13. The User Institution will notify HECG-BU prior to any significant changes to the protocol for the Project. 14. The User Institution will notify HECG-BU as soon as it becomes aware of a breach of the terms or conditions of this agreement. 15. HECG-BU may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies. This clause does not prevent the User Institution from retaining these data for archival purpose in conformity with audit or legal requirements. 16. The User Institution accepts that it may be necessary for the Data Producers to alter the terms of this agreement from time to time. As an example, this may include specific provisions relating to the Data required by Data Producers other than HECG-BU. In the event that changes are required, the Data Producers or their appointed agent will contact the User Institution to inform it of the changes and the User Institution may elect to accept the changes or terminate the agreement. 17. If requested, the User Institution will allow data security and management documentation to be inspected to verify that it is complying with the terms of this agreement. 18. The User Institution agrees to distribute a copy of these terms to the Authorised Personnel. The User Institution will procure that the Authorised Personnel comply with the terms of this agreement. 19. This agreement (and any dispute, controversy, proceedings or claim of whatever nature arising out of this agreement or its formation) shall be construed, interpreted and governed by the laws of England and Wales and shall be subject to the exclusive jurisdiction of the English courts.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
Other

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00005809820 1645228450937 577.6 MB
EGAF00005809821 1645201670387 588.5 MB
EGAF00005809822 1645190160465 566.4 MB
EGAF00005809823 1645190160465 773.6 MB
EGAF00005809824 1645190400307 623.3 MB
EGAF00005809825 1645201741956 627.6 MB
EGAF00005809826 1645201861591 472.4 MB
EGAF00005809827 1645228391061 550.0 MB
EGAF00005809828 1645227878046 588.7 MB
EGAF00005809829 1645227878046 557.8 MB
EGAF00005809830 1645227669376 618.2 MB
EGAF00005809831 1645189922367 548.7 MB
EGAF00005809832 1645227878046 626.6 MB
EGAF00005809833 1645190042367 681.2 MB
EGAF00005810008 1645189560128 492.8 MB
EGAF00005810009 1645201682723 556.6 MB
EGAF00005810010 1645201802047 456.4 MB
EGAF00005810011 1645189680341 476.7 MB
EGAF00005810012 1645189801002 464.9 MB
EGAF00005810013 1645189680342 554.6 MB
EGAF00005810014 1645189743484 480.2 MB
EGAF00005810015 1645201670387 537.1 MB
EGAF00005810016 1645189743484 566.5 MB
EGAF00005810017 1645201670387 435.4 MB
EGAF00005810018 1645189860244 413.5 MB
EGAF00005810019 1645201682723 509.2 MB
EGAF00005810020 1645189743483 472.9 MB
EGAF00005810021 1645189620171 335.2 MB
EGAF00005810022 1645189680341 527.5 MB
EGAF00005810023 1645190160465 567.7 MB
EGAF00005810024 1645189801002 518.8 MB
EGAF00005810025 1645189743483 499.0 MB
EGAF00005810026 1645189743483 585.5 MB
EGAF00005810027 1645189922367 504.9 MB
EGAF00005810028 1645201670387 543.4 MB
EGAF00005810029 1645201741956 458.2 MB
EGAF00005810030 1645201682723 326.9 MB
EGAF00005810031 1645190221025 557.0 MB
EGAF00005810032 1645189801002 472.8 MB
EGAF00005810033 1645201741957 622.8 MB
EGAF00005810034 1645190400307 685.0 MB
EGAF00005810035 1645189922367 314.6 MB
EGAF00005810036 1645201741956 520.1 MB
EGAF00005810037 1645190280376 524.0 MB
EGAF00005810038 1645201861591 515.2 MB
EGAF00005810039 1645189860244 512.2 MB
EGAF00005810040 1645189860244 567.7 MB
EGAF00005810041 1645190160465 522.5 MB
EGAF00005810042 1645201670387 371.8 MB
EGAF00005810043 1645201682723 544.2 MB
EGAF00005810044 1645201741956 602.0 MB
EGAF00005810045 1645189982536 637.6 MB
EGAF00005810046 1645189922367 539.3 MB
EGAF00005810047 1645189922367 494.9 MB
EGAF00005810048 1645201741956 536.0 MB
EGAF00005810049 1645189743483 552.6 MB
EGAF00005810050 1645201682723 554.2 MB
EGAF00005810051 1645189743483 532.0 MB
EGAF00005810052 1645201741956 649.6 MB
EGAF00005810053 1645189982536 520.7 MB
EGAF00005810054 1645189922367 263.0 MB
EGAF00005810055 1645189860244 489.3 MB
EGAF00005810056 1645189860244 452.8 MB
EGAF00005810057 1645201682723 376.5 MB
EGAF00005810058 1645190160465 525.6 MB
EGAF00005810059 1645201682723 472.2 MB
EGAF00005810060 1645190280376 469.1 MB
EGAF00005810061 1645189982536 535.9 MB
EGAF00005810062 1645189922367 535.0 MB
EGAF00005810063 1645201682723 430.9 MB
EGAF00005810064 1645190042367 453.8 MB
EGAF00005810065 1645201682723 460.1 MB
EGAF00005810066 1645201682723 491.1 MB
EGAF00005810067 1645201670387 486.8 MB
EGAF00005810068 1645201670387 566.4 MB
EGAF00005810069 1645189982536 555.3 MB
EGAF00005810070 1645189743483 423.5 MB
EGAF00005810071 1645201741956 475.1 MB
EGAF00005810072 1645190160465 697.3 MB
EGAF00005810073 1645189743483 298.0 MB
EGAF00005810074 1645189801002 433.5 MB
EGAF00005810075 1645201682723 310.5 MB
EGAF00005810076 1645189743483 463.3 MB
EGAF00005810077 1645201741956 485.5 MB
EGAF00005810078 1645189801002 617.1 MB
EGAF00005810079 1645201741956 499.7 MB
EGAF00005810080 1645189680341 502.6 MB
EGAF00005810081 1645201682723 479.3 MB
EGAF00005810082 1645201682723 433.9 MB
EGAF00005810083 1645190160465 355.0 MB
EGAF00005810084 1645189860244 595.1 MB
EGAF00005810085 1645190042367 543.0 MB
EGAF00005810086 1645201741956 586.9 MB
EGAF00005810087 1645201670387 341.2 MB
EGAF00005810088 1645201682723 553.9 MB
EGAF00005810089 1645201670387 454.2 MB
EGAF00005810090 1645201682723 518.6 MB
EGAF00005810091 1645201921484 628.1 MB
EGAF00005810092 1645201670387 487.7 MB
EGAF00005810093 1645201670387 326.2 MB
EGAF00005810094 1645201741956 555.6 MB
EGAF00005810095 1645201741956 283.5 MB
EGAF00007812917 1670242521040 5.7 MB
103 Files (52.0 GB)